Biologic cancer treatments have become incredibly important in oncology, but they can be expensive. Biosimilars are molecules manufactured to replicate the effects of biologics. They give patients and providers a choice and help to drive prices down through competition, but doctors, patients and caregivers need to understand what biosimilars are, what they can do, and the strengths and limits of this new frontier in medicine.
The online discussion was led by John Snowden, the Director of Biosimilars at Amgen Canada, Inc., a biotechnology company based in Mississauga Ontario. He is a founding member and current Co-Chair for the newly formed industry trade association The Canadian Biosimilar Forum.